UroGen Pharma

About UroGen Pharma

UroGen Pharma (Nasdaq: URGN) is a clinical-stage biopharmaceutical company. In January 2026, the company successfully activated its unique J-code (J9282) for ZUSDURI™, dramatically expanding patient access to this first-of-its-kind bladder cancer therapy.